2022
A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G
Weinzimer S, Bailey RJ, Bergenstal RM, Nimri R, Beck RW, Schatz D, Ambler-Osborn L, Schweiger DS, von dem Berge T, Sibayan J, Johnson ML, Calhoun P, Phillip M, Bergenstal R, Phillip M, Criego A, Bergenstal R, Carlson A, Martens T, Beasley S, Johnson M, Whipple D, Hyatt J, Punel A, Grieme A, Thomas L, LaFrance A, Hasledalen C, Laffel L, Isganaitis E, Freiner E, Ambler-Osborn L, Desrochers H, Turcotte C, Naik N, Roethke L, Fisher M, Nimri R, Nevo M, Bello R, Hamou A, Hermon O, Horesh O, Shiovitch Mantzuri G, Drotz I, Yehiel N, Naveh R, Schatz D, Haller M, Albanese-O'Neill A, Sheehan E, Leey J, Smith M, Jacobsen L, Adams J, Hosford J, Whyte L, Battelino T, Dovč K, Bratina N, Šmigoc Schweiger D, Sever U, Gianini A, Murn Berkopec B, Mali B, Weinzimer S, Weyman K, Carria L, Zgorski M, Danne T, Biester T, von dem Berge T, Weiskorn J, Kordonouri O, Biester S, Aschemeier B, Remus K, Pisarek N, Sibayan J, Beck R, Mouse T, Davis J, Bailey R, Hellmann A, Reese N, Calhoun P, Strayer H, Cohen N, Henderson R, Kollman C, Kennedy J, Woodall W, Mahr I, Hood K, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C, Eggerman T. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. Diabetes Technology & Therapeutics 2022, 24: 573-582. PMID: 35363054, PMCID: PMC9353997, DOI: 10.1089/dia.2021.0568.Peer-Reviewed Original ResearchConceptsHybrid closed-loop systemGlucose levelsGlycemic controlGlycemic excursionsAdvanced hybrid closed-loop systemG armPostprandial glycemic excursionsPostprandial glycemic controlType 1 diabetesPostprandial glucose controlPrandial insulin deliveryTreatment armsCrossover trialGlucose controlMedtronic MiniMedSecondary analysisMeal sizeOvernight improvementInsulin deliveryHyperglycemiaOutcomesArmLevel 2HypoglycemiaPremeal
2021
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial
Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M, Group F. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. The Lancet 2021, 397: 208-219. PMID: 33453783, PMCID: PMC9194961, DOI: 10.1016/s0140-6736(20)32514-9.Peer-Reviewed Original ResearchConceptsAdvanced hybrid closed-loop systemType 1 diabetesHybrid closed-loop systemMiniMed 670G systemGlucose levelsCrossover trialYoung adultsMultiple daily insulin injectionsSevere hypoglycaemic eventsDaily insulin injectionsComputer-generated sequencePermuted block designContinuous glucose monitoringBaseline HbACoprimary outcomesEndocrinology practiceHypoglycaemic eventsWashout periodHemoglobin levelsKidney diseaseMean ageInsulin injectionsProportion of timeContinuous glucose monitorImpaired awareness
2018
Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management
Adams RN, Tanenbaum ML, Hanes SJ, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology & Therapeutics 2018, 20: 648-653. PMID: 30239219, DOI: 10.1089/dia.2018.0174.Peer-Reviewed Original ResearchConceptsManagement distressHuman factorsTechnology attitudesGlycemic outcomesType 1 diabetes outcomesHybrid closed-loop systemPsychosocial factorsMultisite clinical trialTrial periodDistressTrial exposureFear of hypoglycemiaDiabetes careOutpatient settingDiabetes outcomesClinical trialsType 1Insulin deliveryTrialsAttitudesOutcomesT-testRegression analysisFurther investigationAdolescentsOptimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care 2018, 41: dc171682. PMID: 29444895, PMCID: PMC6463622, DOI: 10.2337/dc17-1682.Peer-Reviewed Original ResearchConceptsMiniMed 670G systemHybrid closed-loop therapyTotal daily insulin doseYoung adult participantsDaily insulin doseType 1 diabetesOptimal clinical useAdult participantsClosed-loop therapyHybrid closed-loop systemPivotal trialsYounger patientsInsulin doseInsulin ratioClinical guidancePercentage of timeHCL useClinical sitesClinical useMonthsStudy phaseTrialsUse ratesParticipantsDelivery patterns
2017
Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System
Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Science Of Diabetes Self-Management And Care 2017, 43: 223-232. PMID: 28340542, PMCID: PMC7162535, DOI: 10.1177/0145721717697244.Peer-Reviewed Original ResearchConceptsType 1 diabetesHybrid closed-loop systemFirst hybrid closed-loop systemLong-term complicationsGlycemic controlClinical trialsUS FoodDrug AdministrationMethods ThirtyDiabetesLife benefitsInsulin deliveryMental burdenT1DArtificial pancreasConclusion UsersAttitudes of individualsFocus groupsPerceived benefitsIndividualsComplicationsPancreasCliniciansAdministrationTrialsGlucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2016
Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance
Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdolescentAdolescent BehaviorAdultAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringCalibrationCohort StudiesDiabetes Mellitus, Type 1Drug Dosage CalculationsDrug MonitoringGlucoseHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinPancreas, ArtificialPrecision MedicineSubcutaneous TissueYoung AdultConceptsType 1 diabetesAdolescent cohortAdult cohortHybrid closed-loop systemPump therapyPercentage of timeGlucose valuesSensor-augmented pump therapyOverall glucose controlInsulin pump therapyOverall mean percentageDose insulinGlucose controlPreliminary safetyInsulin delivery systemsInitial cohortHybrid closed-loop controlClinical practiceSecond cohortCohortMean percentageTarget rangeOverall percentageDiabetesAdults